SAR439459

Phase 1Small molecule

Sanofi

SAR439459 is one of 23 small molecule programs targeting Osteogenesis Imperfecta. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteogenesis ImperfectaActive, not recruiting

Osteogenesis ImperfectaPhase 1

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Osteogenesis Imperfecta

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

7 2

Neoral

Fosamax

2 4

Forteo

AAlmaject

Approved

2 5

Aredia

HHikma Pharmaceuticals LLC

Approved

2 6

Cytoxan

BBaxter Healthcare Corporation

Busulfex

Prolia

2 9

Risedronate Sodium

Sanofi

Phase 3

2 10

Genotropin

EMD Serono

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Age

NCT04643002

Clinical

Trials by Indication[1]

Age1 trial

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT04643002·258 enrolled

Patients With Advanced Solid Tumors1 trial

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT03192345·161 enrolled

Osteogenesis Imperfecta1 trial

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated· Sanofi logo

Sanofi·Phase 1·NCT05231668·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAR439459. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR439459 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR439459. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

SAR439459

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Age1 trial

Patients With Advanced Solid Tumors1 trial

Osteogenesis Imperfecta1 trial

References

Drug Info

Quick Facts

Related News